In preclinical studies, CDK4/6 inhibition has been shown to decrease cancer stem cell (CSC) populations in breast cancer cell lines40,41, which might help explain why claudin-low gene expression signature enrichment is absent with CCCA in the ribociclib arm. The gene discussed is CDK4; the disease is breast carcinoma.